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Treatment for traumatic brain injury (TBI) is aimed at mitigating the inflammatory 
response and subsequent complications present immediately after injury as well as the chronic 
behavioral complications that can persist months or years following the initial injury. Currently, 
there are no effective treatments to prevent the acute and prolonged neuroinflammation and 
behavioral deficits after a TBI. Methylene blue (MB) is an anti-inflammatory agent and inducible 
nitric oxide synthase (iNOS) inhibitor used clinically to reduce inflammation associated with 
septic shock and hypoperfusion. The purpose of this study was to determine the extent to which 
MB reduced inflammation and behavioral deficits associated with TBI. Adult (2-3 mo) mice 
received a sham injury or moderate and diffuse TBI using a midline fluid percussion injury 
model. Between 5 and 15 min after injury, mice were injected intravenously with sterile water or 
MB. Mice were either sacrificed 24 h later for tissue collection or examined for anxiety, motor 
coordination, and depressive-like behavior at one week after injury. Here we show that a 
moderate TBI increased brain edema in mice 24 h after injury, but was reduced by MB. In 
addition, 24 h after TBI mRNA expression of several neuroinflammatory mediators including IL-
1β and CD14 were increased, but these were also reduced with MB treatment. Moreover, MB 
decreased the inflammatory profile of trafficking macrophages associated with the brain after 
injury. Behaviorally, mice with a TBI had impaired motor coordination up to one week after injury 
and showed evidence of depressive-like behavior at the one week time-point. Treatment with 
MB, however, improved motor coordination up to baseline and reduced TBI-associated 
depressive-like behavior. Taken together, these data indicate that MB may serve as an effective 
clinical treatment to reduce immediate neuroinflammatory events and abrogate chronic 






1.1 Epidemiological Context 
Traumatic brain injury (TBI) is a complex medical condition characterized by acute and 
long-term structural and functional changes to the brain. TBIs are estimated to account for 1.7 
million emergency department visits, 275,000 hospitalizations, and 52,000 deaths per year 
(Faul, et al. 2010). Excluding military related injuries, falls account for largest incidence of TBI 
cases (35.2%), followed by motor vehicle accidents (17.3%), direct physical impact (16.5%), 
assault (10%), and unknown/other causes (21%). Adults aged 75 years and older account for 
the highest rates of TBI-associated hospitalizations. In contrast, children (age 0-4) and 
teenagers (age 15-19) are the highest risk populations of sustaining a TBI. As a consequence of 
lifelong TBI management and medical treatment, an aging population, and increased incidence 
of TBI among military personnel participating in operations in Iraq and Afghanistan, TBIs are 
expected to account for hundreds of billions of dollars in direct medical costs and estimated loss 
of productivity over the next decade (Faul, et. al 2010). The financial burden of TBI, lack of 
effective treatment, and mounting epidemiological evidence suggesting a connection between 
brain injury and neurological conditions including chronic traumatic encephalopathy and major 
depressive disorder, highlight TBI as a major public health concern. 
 
1.2 Pathophysiology of Traumatic Brain Injury  
Traumatic brain injury (TBI) is characterized by two injury phases, an immediate primary 
injury and chronic secondary injury. The primary injury consists of structural damage directly 
resulting from biomechanical impact to the brain including diffuse axonal injury, contralateral 
injury, tissue loss or neuronal death, disruption of neuronal and glial cell membranes, damage to 
vascular structures including the blood-brain barrier, and other complications associated with 
skull fractures in open head injuries (Protheroe and Gwinnutt 2011). The extent of these injuries 
can be inferred through physical examination, use of the well-established Glasgow Coma Scale, 
4 
 
or more directly through neuroimaging, e.g. computed tomography (CT) scan to observe cistern 
formation, parenchymal lesion density, or midline shifts (Farshchian et al. 2012; Greenburg 
2010). Observation of these phenomena is highly dependent on the type and severity of injury. 
All other symptomology of acute clinical relevance including cerebral edema, epi- and subdural 
hematoma, and ischemia are, for the purposes of this discussion, considered components of 
secondary injury in accordance with the most recent literature. 
The secondary injury is characterized by the pathophysiological responses and 
immunopathology associated with the release of prostaglandins, free radicals, complement 
factors, and pro-inflammatory mediators (Ziebell and Morganti-Kossmann 2010). Differential 
expression of these pathological mediators indicates the involvement of many biochemical 
pathways that may contribute to and serve as markers of secondary injury severity. Of these 
inflammatory mediators, interleukin (IL)-1, IL-6, IL-8, IL-10, granulocyte colony-stimulating factor 
(GC-SF), tumor necrosis factor-α (TNF-α), Fas ligand, and monocyte chemoattractant protein-1 
(MCP-1) have received considerable attention over the last decade due to their involvement in 
specific TBI-associated pathologies or reparative processes (Ziebell and Morganti-Kossmann 
2010). For example, IL-1 family cytokines have been shown to exacerbate acute neuronal injury 
in rodent TBI (Rothwell 1999). 
More recent evidence also suggests that these acute inflammatory changes in TBI 
patients may contribute to chronic neurodegeneration, resulting in reduced white matter density 
and corpus callosum thickness following a single traumatic brain injury (Johnson, Stewart et al. 
2013). Although the molecular mechanisms involved in secondary injury pathogenesis are not 
well understood, the potential role of inflammation in promoting primary injury-like progressive 
neurodegeneration highlights the relevance of investigating inflammatory mediators as potential 
therapeutic targets for long-term TBI management. Moreover, the importance of peripherally 
derived inflammatory mediators and systemic pathophysiological responses contributing to 
secondary injury should also be considered. Studies have implicated specific processes such as 
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platelet serotonin release in serum (Valiyaveettil, Alamneh et al. 2013) and more general 
changes such as systemic and peripheral inflammatory responses mediated by myeloid-derived 
cells (Smrcka, Mrlian et al. 2007) following TBI. The relationship between central and systemic 
inflammation or the extent to which either of these processes contribute to long-term 
complications in the context of TBI has yet to be characterized. 
Other soluble mediators of secondary injury include reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) that contribute to central and peripheral inflammatory 
responses and pathophysiological changes in vascular function and blood-brain barrier (BBB) 
permeability. In a different but comparable model of TBI, recent research has elucidated the role 
of ROS and RNS in mediating acute cerebrovascular damage and BBB disruption (Abdul-
Muneer, Schuetz et al. 2013). Leakiness of the BBB may facilitate peripheral cell infiltration and 
soluble immune factor entry into the brain. Exposure of these additional inflammatory elements 
to the brain is hypothesized to underlie the development of various neurodegenerative 
conditions including Alzheimer’s disease and multiple sclerosis (de Vries, Kooij et al. 2012). 
Further understanding of the role these mediators play in pathophysiology and their potential 
utilization as biomarkers of injury severity in human TBI is of widespread interest in current 
neurotrauma research. 
Neuroinflammation, ROS and RNS activity, and cerebrovascular damage not only 
contribute to exacerbated tissue loss and neuronal death beyond that of the primary injury, but 
have also been implicated in the development of depression in experimental models (Dantzer, 
O'Connor et al. 2008) and epidemiological studies. In one large scale study (n=722) of human 
TBI in 2001, 42% of injured patients were determined to have comorbid major depressive 
disorder (MDD), based on DSM-IV criteria, an average of 2.5 years post injury (Kreutzer, Seel et 
al. 2001). In a separate study published the same year (n=91), the authors found that 33% of 
TBI patients were also diagnosed with MDD. Comorbid cases of TBI and MDD have received 
considerable attention in the media following the high profile suicides of several professional 
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players in the National Football League and struggles of combat veterans of Iraq and 
Afghanistan who suffered head trauma. Although TBI is not necessarily directly linked to 
suicide, the comorbid psychopathologies associated with injury, including MDD, substance use 
disorder, assaultive behavior, engagement in dangerous activities, and self-directed violence 
among many others have all been identified as significant risk factors for suicide (Olson-
Madden, Forster et al. 2012). Other long-term complications associated with TBI include post-
concussion syndrome (PCS) and chronic traumatic encephalopathy (CTE). Description, 
diagnosis, and treatment of PCS and CTE remain controversial due to the ambiguous etiology, 
non-specificity of clinical symptoms, and limitations of current studies. PCS is broadly 
characterized by a variety of somatic e.g. headache, vertigo and psychological e.g. irritability, 
anxiety symptoms often following a single TBI (Leddy, Sandhu et al. 2012). In comparison, CTE 
is broadly characterized by similar somatic and psychological symptoms, but also several 
unique post-mortem anatomical markers, e.g. neurofibrillary tangle formation, amyloid plaques 
often observed following repetitive, mild TBIs (Turner, Lucke-Wold et al. 2012; Greenburg 
2010). Evaluation and treatment of PCS and CTE remain an ongoing problem for clinicians. 
Currently, there are no universally accepted or effective medicinal, surgical, or therapeutic 
strategies to manage acute and chronic TBI complications. 
 
1.3 Neuroimmune Basis of Secondary Injury Severity and Behavioral Deficits 
Recent research by our laboratory has emphasized the role of microglia, the innate 
immune cell of the central nervous system (CNS), in mediating acute inflammatory processes in 
the brain when activated in relation to aging, lipopolysaccharide (LPS) insult, repeated social 
defeat, early life infection, and TBI. Preliminary data from our lab demonstrate that following a 
moderate and diffuse TBI in mice, microglia become primed (i.e., increased MHCII expression). 
This is relevant because previous research has established that primed, MHCII+ microglia are 
responsible for exaggerated neuroinflammation. In particular, aging alone was found to promote 
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a primed, MHCII+ microglial population in the brain (Godbout, Chen et al. 2005). Following an 
inflammatory challenge, these MHCII+ microglia become hyper-active and secrete elevated 
levels of the pro-inflammatory cytokine IL-1β into the brain (Henry, Huang et al. 2009) resulting 
in a prolonged sickness response (Godbout, Chen et al. 2005) and induction of depressive-like 
behavior (Godbout, Moreau et al. 2008). Indeed, our previous TBI data indicate that one month 
following a TBI, microglia had increased MHCII expression and, following a peripheral 
inflammatory challenge with LPS, these microglia became hyperactive resulting in exaggerated 
pro-inflammatory cytokine production (i.e., IL-1β, iNOS, TNFα). Importantly, this exaggerated 
neuroinflammation resulted in prolonged sickness behavior in TBI mice injected with LPS. 
Previous studies have also shown that TBI mice demonstrated exaggerated depressive-like 
behavior one week and one month post-injury.  
Upregulation of pro-inflammatory cytokines due to LPS immune challenge is coupled 
with microglial activation. Microglial activation is determined through ionized calcium-binding 
adapter molecule 1 (Iba1) immunohistochemical staining in which cells demonstrate an 
activated morphology characterized by shortened and thickened cell processes and enlarged 
cell bodies (Corona, Huang et al. 2010). An increase in the activated microglia phenotype can 
be observed in the CA1 region of the hippocampus one month following TBI. Exaggerated 
activation of microglia coupled with the significant upregulation of pro-inflammatory cytokines 
has been linked with depressive-like behavior in mice (Godbout, Moreau et al. 2008). Increased 
immobility time in tail suspension test (TST) (Corona, Huang et al. 2010) and forced swim test 
(FST; Godbout, Moreau et al. 2008) are indications of this depressive-like behavior. We 
hypothesized that acute inflammatory processes mediated by activated microglia in the brain 
following injury, underlie secondary injury pathophysiology, and facilitate the development of 
chronic behavioral deficits associated with TBI. 
 
1.4 Recent Therapeutic Strategies 
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 Conventional TBI treatment in an acute care setting is focused on symptomatic 
management of life-threatening complications directly or indirectly related to head trauma e.g. 
spinal cord or musculoskeletal injury. These complications include hematoma formation, 
detrimental changes in cerebral blood flow or cerebral perfusion pressure, threatening increases 
in intracranial pressure, and malignant cerebral edema (Greenburg 2010). Following acute TBI 
management, therapeutic strategies addressing the appearance of PCS or other behavioral and 
cognitive deficits is highly variable. A recent review summarized the multitude of treatment 
paradigms available to clinicians in order to address PCS symptoms. These included withdrawal 
from physical or cognitive exertion immediately following injury, psychotherapy, antidepressant 
use, sensorimotor rehabilitation, and ultimately a progressive increase in cognitive and physical 
activity approximately one week following injury (Leddy, Sandhu et al. 2012). 
 No widely adopted medicinal strategies have, to date, been shown to ameliorate 
neuroinflammation, cerebrovascular damage, and behavioral deficits associated with human 
TBI. However, several medicinal therapies have gained considerable support and have been 
successful. Use of a chemical formulation of progesterone, termed BHR-100, recently entered a 
Phase 3 clinical trial, SyNAPSe®, in 2010 to evaluate its effectiveness in treating severe TBI. 
  Regardless of the success of the SyNAPSe® clinical trial, medicinal treatment of TBI 
remains an area of intense investigation. Here we provide support for the utilization of 
methylene blue, a potential therapeutic drug, for the treatment of neuroinflammation, 
cerebrovascular damage, and behavioral deficits associated with TBI. Methylene blue (MB) is 
unique in its broad range of molecular, cellular, and systemic targets in the central nervous 
system. Of particular relevance to TBI, MB is a potent constitutive and indirect nitric oxide 
synthase (iNOS) inhibitor that targets both the receptor for nitric oxide, soluble guanylate 
cyclase (sGC), and iNOS directly. In this regard, the effect of MB on the iNOS/sGC biochemical 
pathway is well-established. Furthermore, the redox activities of MB facilitate the oxidation of 
both ROS and RNS, and highlight its relevance as a powerful antioxidant (Oz, Lorke et al. 
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2011). In the context of TBI, the antioxidant and iNOS inhibitory activities of MB may serve to 
alleviate the oxidative and nitrosative stresses following injury that mediate BBB disruption and 
cerebrovascular damage. Recent evidence has also shown the beneficial effects of sGC 
inhibition using zinc protoporphyrin IX on edema formation, BBB stability, and serotonin levels in 
a comparable model of closed TBI (Vannemreddy, Ray et al. 2006). Moreover, there are several 
clinical cases in the literature reporting successful MB therapy in severe cases of refractory 
septic shock through restoration of hemodynamic stability (Juffermans, Vervloet et al. 2010; 
Dumbarton, Minor et al. 2011). Recent evidence also suggests MB has potent microglia specific 
anti-inflammatory activities on IL-6 and TNF-α formation in a murine model of amyotrophic 
lateral sclerosis. Taken together, these findings implicate the role of MB in attenuating 
secondary injury pathology associated with microglia specific neuroinflammation and ROS/RNS 
dependent cerebrovascular damage (Dibaj, Zschuntzsch et al. 2012). 
 Alternatively, MB mimics the anti-depressive functions of selective serotonin reuptake 
inhibitors and monoamine oxidase inhibitors, in addition to modulation of both dopaminergic and 
glutamatergic neurotransmitter systems to produce chlorpromazine-like antipsychotic effects 
(Oz, Lorke et al. 2011). Potential reversal of functional deficits in behavior and cognition 
following TBI is of considerable clinical importance due to the inefficacy of current management 
strategies addressing comorbid depression. For these reasons and the other anti-inflammatory 
and anti-oxidant activities discussed previously, we hypothesized that MB treatment following 
TBI would attenuate microglia mediated neuroinflammation, cerebrovascular damage, and 
behavioral complications (Fig. 1). 
 
2. Materials and Methods 
2.1 Animal Use Protocols 
Adult (2-3 mo) BALB/C mice were housed in polypropylene cages and maintained at 25 
°C under a 12 h light/12 h dark cycle with ad libitum access to water and rodent chow. All 
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proposed procedures are in accordance with the National Institute of Health Guidelines for the 
Care and Use of Laboratory Animals and were experimental conditions previously approved by 
The Ohio State University Institutional Laboratory Animal Care and Use Committee. Three 
separate cohorts of mice were used for this study. In the first experiment, blood and brain tissue 
was extracted for qPCR and flow cytometric analysis 24 h post-TBI. In the second experiment, 
brain tissue was extracted for measurement of edema in the cortex 24 h post-TBI. In the third 
experiment, mice were examined for anxiety, motor coordination, and depressive-like behavior 
up to one week following injury and were euthanized 1 m post-TBI for a separate study (data not 
shown).  
 
2.2 Fluid Percussion Injury (FPI) 
Mice received a craniotomy 3 mm in diameter mid-way between Bregma and Lambda 
under ketamine (100 mg/kg body weight [BW]) and xylazine (10 mg/kg BW) anesthesia. 
Following recovery from anesthesia (3-4 h), mice received a midline and diffuse, moderate TBI 
using the Fluid Percussion Injury (FPI) Device (Custom Design&Fabrication, Virginia 
Commonwealth University, Richmond, VA) which induced injury with a micro fluid-pulse of 
saline onto the brain through the craniotomy (Lifshitz, Witgen et al. 2007). Sham control mice 
were subjected to all experimental conditions, excluding the injury. The FPI model induces a 
consistent, moderate and diffuse TBI with a 10-20% mortality rate (Lifshitz, Witgen et al. 2007; 
Lifshitz 2008). 
 
2.3 Intravenous (i.v.) Methylene Blue Injection 
Mice received a 100 µl i.v. injection of vehicle (ddH2O) or dilute 1% methylene blue 
solution (Akorn, Inc; 2 mg/kg BW) between 5 and 15 min following injury. No relevant side 




2.4 Blood and Brain Extraction 
 In the first study, mice were euthanized using a lethal dose of ketamine (200 mg/kg BW) 
and xylazine (20 mg/kg BW) 24 h following injury for tissue collection. Blood was extracted via 
cardiac puncture for flow cytometric analysis of plasma. Brains were extracted and a 1 mm 
coronal brain slice through the FPI impact site for gross mRNA analysis was removed. The 
remaining tissue was used for microglia isolation. 
 
2.5 Microglia Isolation 
Brain tissue was homogenized 24 h post-injury. Enriched microglia were isolated using a 
Percoll density gradient extraction protocol as previously described (Henry, Huang et al. 2008). 
We have previously determined that this results in an “enriched” population of 85-90% pure 
microglia. Enriched microglia were then used for mRNA and flow cytometric analysis (Henry, 
Huang et al. 2009; Wynne, Henry et al. 2010). 
 
2.6 Quantitative PCR (qPCR) Analysis of Brain Slice and Microglia 
 mRNA from the 1 mm coronal brain slice and microglia was isolated using a Tri-Reagent 
RNA Isolation Protocol or spin column PrepEase RNA Spin Kit (Affymetrix) respectively. 
Isolated mRNA was converted to cDNA and analyzed using qPCR to determine changes in pro- 
(IL-1β, CD14, iNOS) and anti-inflammatory (IL-4Rα, IL-4, IL-10, and arginase I) mediator 
expression following TBI and MB administration as previously described (Fenn, Henry et al. 
2012). 
 
2.7 Flow Cytometric Analysis of Plasma and Microglia 
Analysis of plasma and microglial protein surface expression by flow cytometry was 
performed as previously described (Henry, Huang et al. 2008; Henry, Huang et al. 2009). In 
brief, Fc receptors were blocked. Plasma was incubated with anti CD11b and anti GR-1 to 
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characterize monocyte populations in circulation. Microglia were incubated with anti CD11b, anti 
CD14, anti CD45, or anti Ly6C antibodies respectively to characterize inflammatory microglia 
and trafficking macrophage phenotypes (eBioscience, CA). Antigen expression was determined 
using a Becton-Dickinson FACSCaliber four color Cytometer. Ten thousand events were 
recorded. For each antibody, gating was determined based on appropriate negative isotype 
stained controls. Flow data were analyzed using FlowJo software (Tree Star, CA). 
 
2.8 Measurement of Edema 
 In the second experiment, mice were euthanized using a lethal dose of ketamine (200 
mg/kg BW) and xylazine (20 mg/kg BW) 24 h following injury. The brain was extracted, and the 
left and right cortices were dissected out and immediately weighed. Cortices were oven-dried at 
72 °C for 24 h and weighed again to calculate relative percent water loss. No differences in 
percent water loss were observed when brain tissue was oven-dried at 72 °C for 48 or 72 h.  
 
2.9 Behavioral Tests 
 In the third experiment, mice were examined for deficits in anxiety, motor coordination, 
and depressive-like behavior up to one week following injury. Mice were euthanized 1 m 
following injury for a separate analysis (data not shown). 
 The anxiety test was determined as previously described (Kinsey, Bailey et al. 2007; 
Wohleb, Hanke et al. 2011; Wohleb, Fenn et al. 2012). In brief, experimental mice were placed 
in the test apparatus that consisted of a 40 cm x 40 cm x 25 cm Plexiglas box in dim light. Mice 
were placed into the corner of the open-field and locomotor activity was recorded for 5 min 
using an automated system and analyzed using VersaMap software (AccuScan Instruments, 
Columbus, OH). Schematic diagrams of mouse position and the number of center entries, into 
the open field, were recorded for analysis. 
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 Motor coordination was determined using a Rotarod testing apparatus before and after 
injury. Mice were placed on the stationary rod 3 d before injury in order to be acclimated to the 
Rotarod testing setup. Mice were placed on the rod at constant revolution (5 revolutions/min) 2 
d before injury to complete acclimation to the testing paradigm. Motor coordination was then 
determined by the time spent on the Rotarod at the experimental angular velocity (10 
revolutions/min) and acceleration (0.2 revolutions/min2) 1 d before injury. Testing continued at 4 
h and 1, 3, 5, and 7 d post-TBI. Each mouse was tested in three separate trials. The first and 
second trials were performed consecutively; the third trial was performed 10 min after the 
second trial. The two closest performance times among the were averaged and used for each 
mouse in this analysis. 
The tail suspension test (TST) was used to determine depressive-like behavior. This 
model is an established and accepted model of resignation behavior in mice (Godbout, Moreau 
et al. 2008; Corona, Huang et al. 2010). In brief, mice were suspended by their tail in a 32 x 33 x 
33 box under dim conditions for 10 min. Immobility times, as a measure of resignation behavior, 
were recorded by a trained observer blind to experimental conditions. 
 
2.10 Statistics 
To ensure a normal distribution, data was subjected to Shapiro-Wilk test using Statistical 
Analysis Systems (SAS) software (Cary, NC). Observations greater than 3 interquartile ranges 
from the first and third quartile were considered outliers and were excluded in the subsequent 
analysis. To determine significant main effects and interactions between main factors, data was 
analyzed using one- (TBI; MB) or two- (TBI x MB) way ANOVA using the General Linear Model 
procedures of SAS. When appropriate, differences between treatment means were evaluated 
by an F-protected t-test using the Least-Significant Difference procedure of SAS. Significance 
was determined at p < 0.05 and indicated by (*) or letter notation (a, b) to demonstrate 
statistically significant differences between groups. Where noted, a simple one-tailed T-test with 
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equal variance was used to determine significance (p < 0.05) for Post-hoc analysis and was 
indicated by (+).  
 
3.0 Results 
3.1 MB Abrogated TBI-induced Inflammatory Mediators in the Brain 
 In previous studies using our FPI model of TBI, we found microglial (IL-1β) and 
astrocytic (GFAP) markers of inflammation were significantly upregulated 4 and 72 h post-TBI 
respectively in the cortex and hippocampus (data not shown). Our aim was to first examine the 
effect of MB treatment on pro- and anti-inflammatory markers in the 1 mm coronal brain slice as 
an estimate of gross mRNA expression in the brain. mRNA concentrations of several 
inflammatory: A) IL-1β, B) iNOS, and C) CD14 and anti-inflammatory mediators: D) arginase I, 
E) IL-10, F) IL-4Rα and G) IL-4 were measured 24 h following injury (Fig. 2). Our preliminary 
results have shown that TBI induced a noted upregulation of IL-1β and CD14, both of which 
were reduced by MB. Alternatively, MB increased expression of anti-inflammatory mediators in 
the brain, including IL-4 and IL-10; however, no significant statistical interactions were identified. 
These data indicate that TBI induced an acute inflammatory response in the brain that was 
reduced by MB. 
 
3.2 MB Abrogated TBI-Induced Expression of Inflammatory Mediators in Microglia 
 Once the effect of MB treatment on inflammatory mediators was established in whole 
brain tissue, we continued our studies on microglia specific populations. mRNA concentrations 
of several inflammatory: A) IL-1β, B) CD14, C) iNOS and anti-inflammatory mediators: D) 
arginase I, E) IL-10 and F) IL-4Rα were measured from isolated microglia (Fig. 3). Our aim was 
to evaluate the role of microglia in mediating inflammatory responses 24 h following injury 
through analysis of both pro- and anti-inflammatory mediators. Again, both IL-1β and CD14 
were upregulated following injury, and were subsequently reduced after treatment with MB. 
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Furthermore, expression of IL-10 increased with MB treatment. Arginase I was significantly 
upregulated following injury (TBI x Vehicle) compared to Sham x Vehicle and TBI x MB (p = < 
0.03) and to a lesser extent Sham x MB (p = 0.10). No other significant interactions were 
identified. These data indicate that microglia significantly upregulated arginase activity 24 h 
following injury and contributed to acute neuroinflammation. The effect of MB on arginase 
indicated that MB had a significant effect on microglia; however, the mechanism of this activity 
remains to be elucidated. 
 
3.3 MB Did Not Reduced CD14 Protein Expression on Microglia after TBI 
 Although qPCR analysis provided a broad profile of pro- and anti-inflammatory mediator 
expression in the whole brain and microglia, the physiological relevance of these data was 
unsubstantiated. We chose to examine the relative percentage of CD11b+/CD14high microglia, an 
established reactive and inflammatory phenotype, through flow cytometric analysis of surface 
protein expression 24 h following injury (Fig. 4). CD14 expression significantly increased with 
TBI (p = 0.0004) but there was no significant reduction following MB treatment (p = 0.6). These 
data indicate that microglial activation, as evaluated through CD14, associated with TBI but was 
unaffected by MB treatment. 
 
3.4 MB Had No Effect on Trafficking Macrophages after TBI 
 The microglia extraction protocol used in this experiment (Materials and Methods 2.5) 
cannot differentiate between isolation of microglia and trafficking macrophages. Macrophage 
populations in whole brain tissue can however be identified through flow cytometric analysis of 
macrophage specific surface protein expression (CD11b+/CD45high or CD11b+/Ly6Chigh). 
Analysis of CD11b+/CD45high cells was conducted to measure the relative percentage of 
macrophages associated with the extracted brain sample 24 h following injury (Fig. 5A).  The 
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relative percentage of CD11b+/CD45high cells significantly increased with TBI (p = 0.015) but 
there was no significant reduction with MB treatment (p = 0.65). 
 Moreover, we attempted to examine differences in the relative percentage of 
inflammatory trafficking macrophages, CD11b+/Ly6Chigh, associated with the brain 24 h post-
injury (Fig. 5B). No significant differences were attributed to TBI (p = 0.18) or MB (p = 0.66); 
however, there was a minor interaction between the Sham x Vehicle and TBI x Vehicle groups 
(p = 0.08) that was also observed through Post-hoc analysis (p = 0.06). Taken together, these 
data indicate that MB has no effect on TBI-induced macrophage trafficking, but the inflammatory 
profile of these cells may be attenuated by MB. 
 
3.5 MB Attenuated the Inflammatory Profile of Myeloid Cells in Circulation 
 Analysis of trafficking macrophages was extended to myeloid-derived monocyte 
populations in circulation in order to determine the phenotype of prospective inflammatory cells 
24 h following injury. The relative percentage of CD11b+/GR-1+ cells through flow cytometry 
(quantitative analysis and representative dot plots shown in Fig. 6A and Fig. 6B respectively) 
were measured. No significant interactions were identified; however, there was a minor 
interaction associated with TBI (p = 0.07) that was reversed by MB (p = 0.14). These data 
indicate that TBI can affect the inflammatory profile of peripheral cells, and that this interaction 
may be reduced by MB treatment. The extent to which these activated monocyte populations 
affected macrophage trafficking warrants further investigation. 
 
3.6 MB Reduced TBI-induced Edema 
 Although not thoroughly characterized, our previous studies indicated that edema was 
induced by our TBI model and could be successfully measured (data not shown). Considering 
the clinical relevance of edema in human TBI, our aim was to reduce the formation of edema 
with MB treatment. Using the same methods as our previous experiments, the left and right 
17 
 
cortices were removed from each extracted brain 24 following injury and oven-dried to evaluate 
the relative percent water loss as a measure of edema (Fig. 7). No significant interactions were 
identified; however, the TBI x Vehicle group differed from the Sham x Vehicle group by a simple, 
one-tailed T-Test (p = 0.10), indicating that edema was successfully induced by our model and 
that MB treatment may have a reversing effect. No other minor interactions by a simple, one-
tailed T-test were observed between the remaining groups. 
 
3.7 MB Reversed TBI-induced Deficits in Anxiety, Motor Coordination, and Depressive-
like Behaviors 
 Our lab has extensively studied the effect of inflammatory mediators in the brain and 
periphery on behavior. Here we have used the same behavioral tests in the context of TBI and 
MB treatment. Our aim was to connect the inflammatory profile of microglia to observable 
behavior deficits up to 7 d following injury. Mice were tested for anxiety behavior (representative 
and quantitative analysis of the test in Fig. 8A and Fig. 8B respectively) in an open field setup 
(Materials and Methods 2.9). No significant interactions were identified, but there was a noted 
increase in the number of center entries induced by TBI compared to sham controls that was 
reduced by MB (Fig. 8B). 
 Furthermore, we used a Rotarod test to evaluate the effect of TBI on motor coordination 
(Fig. 8C). Time spent on the Rotarod was recorded up to 7 d following injury. Again, no 
significant interactions were identified but there was an observable separation among the 
treatment groups at 7 d with the TBI x Vehicle group performing at baseline, whereas the Sham 
x Vehicle, Sham x MB, and TBI x MB groups had improved above baseline performance. 
 Lastly, mice were also examined for depressive-like behavior using our tail suspension 
test (TST; Materials and Methods 2.9). Immobility times were recorded as a measure of 
depressive-like activity (Fig. 8D). No significant interactions were identified, but there was an 
increase in immobility time associated with TBI that was reversed by MB treatment. Overall, 
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these data indicate that MB promoted self-preservation behavior in the open field test, reversed 
motor coordination benefits in the Rotarod test, and attenuated depressive-like behavior in the 
TST associated with TBI up to 7 d following injury. 
 
4. Discussion 
 In our previous studies, inflammatory microglial and astrocytic markers were differentially 
upregulated in relation to time and brain region following injury (data not shown). An important 
finding of this preliminary study was to demonstrate the development of an acute inflammatory 
response in the whole brain (Fig. 2) and microglia (Fig. 3) 24 h after TBI that was reduced by 
MB treatment. In particular, the inflammatory mediators IL-1β (Fig. 2A and Fig. 3A) and CD14 
(Fig. 2B and Fig. 3C) were upregulated in the 1 mm coronal brain section and microglia after 
injury. Expression of these markers was downregulated with MB. Alternatively, expression of the 
anti-inflammatory cytokine IL-10 (Fig. 2E and Fig. 3E) increased with MB treatment following 
injury in the brain slice and microglia. Taken together, these data indicate that acute 
neuroinflammation associated with TBI was reduced by MB treatment.  
Furthermore, microglial arginase I was significantly upregulated with TBI (Fig. 3D) but 
reduced with MB (p = < 0.03), whereas no significant interaction was identified with iNOS 
activity. The clinical relevance of these data is unclear. Recent evidence has shown that 
arginase I and iNOS are inversely regulated by SHP-1, a tyrosine phosphatase in microglia, in 
response to innate immune system activation (Bonaparte, Hudson et al. 2006). Moreover, the 
pathophysiological interaction between arginase and iNOS are unclear. For example, arginase 
overexpression is associated with the consumption of bioavailable L-arginine that can hasten 
the iNOS-mediated formation of reactive nitrogen species (RNS; Wink, Hines et al. 2011). As 
previously discussed, RNS disrupt the blood-brain barrier and damage the cerebrovasculature 
(Abdul-Muneer, Schuetz et al. 2013). Although our model has not been shown to induce 
neuronal death (Lifshitz, Kelley et al. 2007), we anticipate the significant upregulation of 
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arginase I associated with TBI is indicative of cellular repair of damaged neurons and glial cells. 
In this regard, reduction in arginase I expression following MB treatment may indicate acute 
neuroprotective activity and limit the necessity of arginase-mediated cellular repair processes. In 
contrast, the effects of arginase I downregulation on RNS formation and the pathophysiological 
consequences of increased L-arginine bioavailability remain to be elucidated. 
Our data support the idea that microglial activation and acute neuroinflammation persist 
in the brain 24 h following TBI. In support of this idea, our first aim was to establish the 
phenotype of resident microglia and trafficking macrophages at the protein level through flow 
cytometric analysis. The relative percentage of CD14high microglia was significantly upregulated 
with TBI but no effect was observed following MB treatment. Rather, histological analysis of 
microglial morphology through Iba1 immunohistochemical staining would provide a more 
appropriate analysis of microglial activation (Corona, Huang et al. 2010) and the therapeutic 
effect of MB. Moreover, the relative percentage of CD11b+/CD45high cells significantly increased 
following TBI (p = 0.015) but was unaffected by MB. In contrast, no significant interactions were 
associated with TBI or MB on the relative percentage of CD11b+/Ly6Chigh cells. Post-hoc 
analyses of these data indicate that MB treatment may attenuate the inflammatory profile of 
these cells (p = 0.06). Taken together, these data indicate that macrophage trafficking is 
associated with TBI, and MB treatment may attenuate the inflammatory profile of the cells 
following injury; however, the specific phenotype and infiltrative capacities of trafficking 
macrophages after TBI remain uncharacterized in this study. Alternatively, our second aim was 
to examine the role of prospective infiltrative and inflammatory monocytes through flow 
cytometric analysis. We determined an increase in the relative percentage of inflammatory 
CD11b+/GR-1+ cells that had a tendency to associate with TBI (p = 0.07) but was reduced with 
MB treatment (p = 0.14). These data indicate that MB attenuated the inflammatory profile of 
circulating myeloid cells that may further serve to limit the infiltration of trafficking macrophages 
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in the brain. Overall, these data demonstrate that MB has an effect on resident microglia, 
trafficking macrophages, and circulating myeloid cells that is worthy of further investigation. 
An interesting finding from this study was that edema formation was successfully 
induced and measured in our FPI model of TBI. Although no major significant interactions were 
observed, the relative percentage of water loss in the TBI x Vehicle group had a tendency to 
differ significantly from the remaining groups (Sham x Vehicle, Sham x MB, and TBI x MB) by a 
simple, one-tailed T-test (0.10). These outcomes are encouraging and suggest that MB may 
serve as an effective medicinal treatment for post-TBI edema formation, particularly in 
comparison to conventional treatment strategies. In this context, MB has emerged as a prime 
candidate for potential therapeutic use in reducing brain edema. In addition, due to the surgical 
protocol required for our FPI model (Materials and Methods 2.2), we anticipate our data reflect a 
conservative estimate of edema formation in the TBI x Vehicle and TBI x MB groups i.e. all mice 
underwent craniectomy (3 mm burr hole) without damage to the meningeal layers. We argue 
that in absence of the craniectomy, the formation of edema and therapeutic efficacy of MB 
would be enhanced. 
These data alone characterizing the anti-inflammatory and medicinal effects of MB 
treatment on TBI provide a strong foundation for the clinical application of MB in CNS trauma. A 
novel aspect of this study however was the effect of MB treatment on anxiety, motor 
coordination, and depressive-like behaviors up to 7 d following injury. In this regard, we have 
established the role of neuroinflammation in the development of depressive-like behavior 
(Godbout, Moreau et al. 2008). Clinically, neuroinflammation has also been shown to mediate 
neurologic complications. For example the chemotherapeutic drug, ifosfamide, is well-known to 
induce encephalopathy and neurotoxicity associated with behavioral complications such as 
delirium and depressive psychosis. In these cancer patients, MB is the treatment of choice and 
has been shown to completely reverse neurologic and behavioral symptoms (Pelgrims, De Vos 
et al. 2000; Brunello, Basso et al. 2007). Our data contribute to the literature characterizing the 
21 
 
activity of MB on reversing these functional deficits. Likewise, in an open field test for anxiety 
behavior, there was a noted increase in the number of center entries, an inverse measure of 
self-preservation and anxiety behavior, associated with TBI that was reversed by MB treatment 
(Fig. 8B). These data suggest TBI inhibited baseline anxiety behavior in BALB/C mice and MB 
acted to restore this phenotype. These data are supported by corroborating findings in human 
TBI e.g. engagement in dangerous activities and self-directed violence (i.e. inhibition of self-
preservation behavior) are characteristic TBI symptoms. Furthermore, in the Rotarod test for 
motor coordination, there was an observable separation among the experimental groups in 
performance 7 d after TBI (Fig. 8C). At this time point, the Sham x Vehicle, Sham x MB, and TBI 
x MB outperformed the TBI x Vehicle group. Lastly, in our tail suspension test for depressive-
like behavior, there was an increase in immobility time in the TBI x Vehicle group that was 
reduced by MB treatment (Fig. 8D). As previously discussed, the prevalence of major 
depressive disorder in TBI patients is a well characterized complication in humans. No 
significant interactions were identified in these preliminary studies; however, our results suggest 
that a single dose of MB (2 mg/kg) immediately following injury may be sufficient to prevent 
behavioral complications up to 7 d post-TBI. The efficacy of multiple MB injections, at or higher 
than the current dosage (2 mg/kg), on acute neuroinflammation or associated behavioral 
complications remains to be elucidated. These data highlight the clinical relevance of 
ameliorating TBI-induced anxiety and major depressive disorder in humans through medicinal 
therapy, and establish MB as a potential drug for these purposes. 
In conclusion, our model of moderate fluid percussion-induced traumatic brain injury, 
successfully demonstrated the development of acute neuroinflammation, edema, and behavioral 
deficits 24 h following injury. In particular, TBI upregulated the expression of inflammatory IL-1β 
and CD14 in the whole brain and resident microglia. The specific role of these microglia in 
mediating acute neuroinflammation, edema, and behavioral deficits associated with TBI remain 
to be elucidated; however, these data suggest resident microglia mediate IL-1β and arginase 
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dependent pathophysiological responses. Additional studies will be required in order to examine 
microglial activation at various time points following injury. Furthermore, TBI increased the 
number of inflammatory monocytes associated with the brain and in circulation. Lastly, TBI 
induced acute behavioral deficits in anxiety, motor coordination, and depressive-like behavior up 
to 7 d post-injury. Intravenous administration of MB immediately following injury acted to reduce 
inflammatory gene expression in the whole brain and resident microglia, decreased the 
inflammatory profile of trafficking macrophages and peripheral monocytes 24 h after TBI, and 
reversed deficits in anxiety, motor coordination, and depressive-like behaviors up to 7 d 
following injury. Taken together these results indicate that early intervention with MB following 
moderate injury reduced inflammatory and behavioral consequences of TBI. Thus, MB 
treatment could reduce immediate life-threatening complications, including malignant cerebral 
edema. Moreover, early MB treatment has the potential to promote long-lasting neurologic 
improvements in TBI patients including reduced development of major depressive disorder. 






























































Fig. 1 Hypothetical Effects of MB Treatment on Secondary Injury in TBI.  Adult mice (2-3 
mo) received a moderate, diffuse TBI and were examined for neuroinflammation, edema 
formation, and behavioral deficits following injury. MB treatment was hypothesized to A) 
attenuate microglial activation (Fig. 3 and Fig. 4), B) ameliorate inflammatory cytokine 
upregulation (Fig. 2 and Fig. 3), C) prevent reactive oxygen and reactive nitrogen species 
formation, D) lessen blood-brain barrier disruption, E) inhibit macrophage trafficking (Fig. 5), F) 
reduce edema (Fig. 7), G) and abrogate behavioral deficits (Fig. 8) associated with TBI. Reactive 
oxygen species (ROS), reactive nitrogen species (RNS), blood-brain barrier (BBB). 
 
Fig. 2 MB Abrogated TBI-induced Inflammatory Mediators in the Brain. Adult (2-3 mo) mice 
received a sham injury or moderate TBI and were immediately injected (i.v.) with vehicle or 1 % 
methylene blue (2 mg/kg). After 24 h mice were sacrificed, the brain was collected, and a 1 mm 
coronal section was dissected. mRNA concentrations of A) IL-1β, B) iNOS, C) CD14, D) 
arginase, E) IL-10, F) IL-4Rα, and G) IL-4 were determined by qPCR. Bars represent the mean 
± SEM. No significant interactions were identified. 
 
Fig. 3 MB Abrogated TBI-Induced Expression of Inflammatory Mediators in Microglia. 
Adult (2-3 mo) mice received a sham injury or moderate TBI and were immediately injected (i.v.) 
with vehicle or 1 % methylene blue (2 mg/kg). After 24 h a coronal brain section was removed 
for gross mRNA analysis (Fig. 2), and microglia were isolated from the remainder of the brain 
tissue. mRNA concentrations of A) IL-1β, B) CD14, C) iNOS, D) arginase, E) IL-10, and F) IL-
4Rα in microglia were determined by qPCR. Bars represent the mean ± SEM. Arginase I was 
significantly upregulated following injury (TBI x Vehicle) compared to Sham x Vehicle and 
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TBI x MB (p = < 0.03) indicated by (*) and to a lesser extent Sham x MB (p = 0.10). No 
other significant interactions were identified. 
 
Fig. 4 MB Did Not Reduced CD14 Protein Expression on Microglia after TBI. Adult (2-3 mo) 
mice received a sham injury or moderate TBI and were immediately injected (i.v.) with vehicle or 
1 % methylene blue (2 mg/kg). After 24 h microglia were isolated and CD14 protein expression 
was determined by flow cytometry. Quantitative analysis for CD14high expression is shown. Bars 
represent the mean ± SEM. CD14 expression significantly increased with TBI (p = 0.0004) 
indicated by (b) but there was no significant reduction following MB treatment (p = 0.6). 
 
Fig. 5 MB Had No Effect on Trafficking Macrophages after TBI. Adult (2-3 mo) mice 
received a sham injury or moderate TBI and were immediately injected (i.v.) with vehicle or 1 % 
methylene blue (2 mg/kg). Microglia/macrophages were isolated from the brain and analyzed by 
flow cytometry for the relative percentage of A) CD11b+/CD45high and B) CD11b+/Ly6Chigh cells. 
Bars represent the mean ± SEM. CD45high expression of CD11b+ cells significantly increased 
with TBI (p = 0.015) indicated by (b) but there was no significant reduction with MB treatment (p 
= 0.65). In the analysis of CD11b+/Ly6Chigh no significant differences were attributed to TBI (p = 
0.18) or MB (p = 0.66); however, there was a minor interaction between the Sham x Vehicle and 
TBI x Vehicle groups (p = 0.08) that was also observed through Post-hoc analysis (p = 0.06) 
indicated by (+). 
 
Fig. 6 MB Attenuated the Inflammatory Profile of Myeloid Cells in Circulation. Adult (2-3 
mo) mice received a sham injury or moderate TBI and were immediately injected (i.v.) with 
vehicle or 1 % methylene blue (2 mg/kg). After 24 h blood was analyzed for the percentage of 
CD11b+/GR-1+ cells in circulation by flow cytometry. Representative dot plots (A) and 
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quantitative analysis are shown (B). No significant interactions were identified; however, there 
was a minor interaction associated with TBI (p = 0.07) indicated by (*) that was reversed by MB 
(p = 0.14). 
 
Fig. 7 MB Reduced TBI-induced Edema. Adult (2-3 mo) mice received a sham injury or 
moderate TBI and were immediately injected (i.v.) with vehicle or 1 % methylene blue (2 mg/kg). 
The left and right cortices were dissected out after 24 h and were weighed. Cortices were oven-
dried at 72 °C for 24 h and weighed to calculate percent water loss. Bars represent the mean ± 
SEM. No significant interactions were identified; however, the TBI x Vehicle group differed from 
the Sham x Vehicle group by a simple, one-tailed T-Test (p = 0.10) indicated by (+). No other 
interactions by a simple, one-tailed T-test were observed between the remaining groups. 
 
Fig. 8 MB Reversed TBI-induced Deficits in Anxiety, Motor Coordination, and Depressive-
like Behaviors. Adult (2-3 mo) mice received a sham injury or moderate TBI and were 
immediately injected (i.v.) with vehicle or 1 % methylene blue (2 mg/kg). Mice were tested for 
anxiety behavior in an open field setup. Representative travel plots are shown in (A) and the 
number of entries into the center in (B). Furthermore, mice were tested for motor coordination 
on Rotarod from -2 to 8 d post-TBI (C). At 7 d following injury, mice were tested for depressive-
like behavior using a tail suspension test. Immobility times are shown in (D). Bars represent the 
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